Aquarius Population Health

Dravet syndrome (DS) is a rare epileptic encephalopathy that is diagnosed in early infancy and extends through adulthood.   Fenfluramine (FFA) is a recently licensed add-on therapy for the treatment of seizures in patients with DS aged 2 years and older.

This work presents a novel individual-level simulation modelling approach to calculate the cost-effectiveness of FFA compared with cannabidiol plus clobazam as an add-on therapy for DS patients in England. Results indicate that FFA is a cost-effective intervention.

presentation_icon


Weston G, Pinsent A, Adams EJ, Linley W, Hawkins N, Schwenkglenks M, Hamlyn Williams C, Toward T. A Cost-Effectiveness Analysis of Fenfluramine for the Treatment of Seizures for Patients with Dravet Syndrome (DS) in the UK Setting. Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 Congress, May 17 – 20, 2021; Virtual

Read Publication

Back to all publications